Cost‐Effectiveness of Carbidopa‐Levodopa Enteral Suspension for Advanced Parkinson's Disease in the United States

Abstract Background Carbidopa/levodopa enteral suspension (CLES) is indicated for the treatment of advanced Parkinson's disease (aPD) with severe motor fluctuations. Objective To determine the cost, quality‐adjusted life years (QALY), and cost‐effectiveness of CLES compared to the standard‐of‐care (SoC) for aPD patients in the United States (US), using real‐world data. Methods A published Markov model, comprising of 25 health states and a death state, (defined by a combination of the Hoehn and Yahr scale and waking time spent in OFF‐time) was adapted to estimate the benefits for CLES versus oral SoC over a patient's lifetime in the US healthcare setting. Clinical inputs were based on a clinical trial and a registry study; utility inputs were sourced from the Adelphi‐Disease Specific Programmes. Results CLES compared to SoC was associated with incremental costs ($1,031,791 vs. $1,025,180) and QALY gain (4.61 vs. 3.76), resulting in an incremental cost‐effectiveness ratio of $7711/QALY. Conclusion CLES is a cost‐effective treatment for aPD patients with medication resistant motor fluctuations. © 2023 AbbVie, Inc and The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.